Senolytic compounds and compositions
AssigneeNuchido Limited
InventorsNichola Jane Conlon, Malcolm Philip Young
Life of this patent
Estimating the term…
Abstract
There is described the use of an agent in the manufacture of a therapy for the treatment or alleviation of a senescence-associated disease, disorder or effect, wherein the agent is selected from one or more of A42548, A425619, alpha lipoic acid, apigenin, Artemisinin, BML-288, BTBHQ, EGCG, fluphenazine dihydrochloride, honokiol, LE300, magnolol, niclosamide, nicotinamide, nordihydroguaiaretic acid, quercetin, resveratrol and a mitochondrial uncoupler. There is also described the use of a mitochondrial uncoupler as an agent for the treatment of a senescence-associated disorder; and the use of an uncoupler in association with a senolytic agent.
Claims54
1-30. (canceled)
A composition comprising an amount of an agent effective for the treatment or alleviation of a senescence-associated disease, disorder or effect, wherein the agent is selected from one or more of A42548, A425619, alpha lipoic acid, apigenin, Artemisinin, BML-288, BTBHQ, EGCG, fluphenazine dihydrochloride, honokiol, LE300, magnolol, niclosamide, nicotinamide, nordihydroguaiaretic acid, quercetin, resveratrol and a mitochondrial uncoupler.
33-40. (canceled)
42-44. (canceled)
46-48. (canceled)
(canceled)
62-65. (canceled)
A composition comprising an amount of an agent effective for the treatment or alleviation of a senescence-associated disease, disorder or effect, wherein the agent is a mitochondrial uncoupler.
A composition comprising a mitochondrial uncoupler in association with an amount of an agent effective for the treatment or alleviation of a senescence-associated disease, disorder or effect.
(canceled)
74-91. (canceled)
A method of mitigation, alleviation or improvement of the senescence-associated effects of ageing in a host, said method comprising the administration of an effective amount of a composition comprising one or more of A42548, A425619, alpha lipoic acid (B), apigenin (C), Artemisinin, BML-288, BTBHQ, EGCG (H), fluphenazine dihydrochloride, honokiol, LE300, magnolol, niclosamide, nicotinamide (F), nordihydroguaiaretic acid, quercetin (G), resveratrol (A) and a mitochondrial uncoupler.
93-111. (canceled)
113-116. (canceled)
(canceled)
125-134. (canceled)
139-142. (canceled)
144-157. (canceled)
Dependencies are inferred from the claim text.